Post-earnings recap
Reported
Wed, Apr 24, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's earnings report indicates a slight miss on EPS expectations, which contributed to a 1.25% decline in stock price. The company is facing market challenges, but management remains focused on long-term growth through innovation. Investors may be cautious as there was no guidance update provided.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.35 | N/A | -5.98% |
Overall, management conveyed a sense of cautious optimism despite missing EPS expectations. They are committed to navigating current market challenges.
Management highlighted ongoing challenges in the market but remains focused on long-term growth.
They emphasized the importance of innovation in driving future sales.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—